These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21221704)

  • 1. Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS.
    Plettenberg A; Brockmeyer NH; Haastert B; Michalik C; Dupke S; Schewe K; Rausch M; Hower M; Ulmer A; Wolf E; Lorenzen T; Arendt G; Jansen K;
    Infection; 2011 Feb; 39(1):3-12. PubMed ID: 21221704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.
    Writing Committee for the CASCADE Collaboration
    Arch Intern Med; 2011 Sep; 171(17):1560-9. PubMed ID: 21949165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
    PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
    ; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
    Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.
    Lodi S; Phillips A; Logan R; Olson A; Costagliola D; Abgrall S; van Sighem A; Reiss P; Miró JM; Ferrer E; Justice A; Gandhi N; Bucher HC; Furrer H; Moreno S; Monge S; Touloumi G; Pantazis N; Sterne J; Young JG; Meyer L; Seng R; Dabis F; Vandehende MA; Pérez-Hoyos S; Jarrín I; Jose S; Sabin C; Hernán MA;
    Lancet HIV; 2015 Aug; 2(8):e335-43. PubMed ID: 26423376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ cells recovery in HIV positive patients with severe immunosuppression at HAART initiation at Centre Medico-Social Cor-Unum, Kigali.
    Merci NM; Emerence U; Augustin N; Habtu M; Julie I; Angelique T; Jessica B; Cynthia A; Penda AT
    Pan Afr Med J; 2017; 26():14. PubMed ID: 28450993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
    Ho C; Lee S; Wong Kh; Cheng L; Lam M
    HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed-type hypersensitivity (DTH) test anergy does not impact CD4 reconstitution or normalization of DTH responses during antiretroviral therapy.
    Minidis NM; Mesner O; Agan BK; Okulicz JF
    J Int AIDS Soc; 2014; 17(1):18799. PubMed ID: 24499779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.
    Cingolani A; Cozzi Lepri A; Castagna A; Goletti D; De Luca A; Scarpellini P; Fanti I; Antinori A; d'Arminio Monforte A; Girardi E
    Clin Infect Dis; 2012 Mar; 54(6):853-61. PubMed ID: 22157323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late initiation of HAART among HIV-infected patients in Spain is frequent and related to a higher rate of virological failure but not to immigrant status.
    Pérez-Molina JA; Suárez-Lozano I; Del Arco A; Teira R; Bachiller P; Pedrol E; Martínez-Alfaro E; Domingo P; Mariño A; Ribera E; Antela A; de Otero J; Navarro V; González-García J;
    HIV Clin Trials; 2011; 12(1):1-8. PubMed ID: 21388936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution.
    Arici C; Ripamonti D; Ravasio V; Maggiolo F; Rizzi M; Finazzi MG; Suter F
    Int J STD AIDS; 2001 Sep; 12(9):573-81. PubMed ID: 11516366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Declines in highly active antiretroviral therapy initiation at CD4 cell counts ≤ 200 cells/μL and the contribution of diagnosis of HIV at CD4 cell counts ≤ 200 cells/μL in British Columbia, Canada.
    Lourenço L; Samji H; Nohpal A; Chau W; Colley G; Lepik K; Barrios R; Lima V; Hogg RS; Montaner J; Kesselring S; Moore DM
    HIV Med; 2015 Jul; 16(6):337-45. PubMed ID: 25721157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL.
    Kaplan JE; Hanson DL; Cohn DL; Karon J; Buskin S; Thompson M; Fleming P; Dworkin MS;
    Clin Infect Dis; 2003 Oct; 37(7):951-8. PubMed ID: 13130408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis on antiretroviral therapy efficacy for HIV/AIDS in Zhejiang province, 2009-2014].
    Zheng JL; Xu Y; He L; Jiang J; Zhang JF; Zhang WJ; Ding XB; Yang JZ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 May; 37(5):673-7. PubMed ID: 27188360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression.
    Gianotti N; Marchetti G; Antinori A; Saracino A; Gori A; Rizzardini G; Lichtner M; Bandera A; Mussini C; Girardi E; dʼArminio Monforte A; Cozzi-Lepri A
    J Acquir Immune Defic Syndr; 2017 Dec; 76(4):417-422. PubMed ID: 28816721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of geographic origin, sex, and HIV transmission group on the outcome of first-line combined antiretroviral therapy in France.
    de Monteynard LA; Matheron S; Gilquin J; Pavie J; de Truchis P; Grabar S; Launay O; Meynard JL; Khuong-Josses MA; Rey D; Simon A; Mahamat A; Dray-Spira R; Costagliola D; Abgrall S;
    AIDS; 2016 Sep; 30(14):2235-46. PubMed ID: 27428741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.